CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting
23 Mayo 2024 - 6:00AM
Business Wire
Oral presentation in “Developmental
Therapeutics-Immunotherapy” session on Sunday, June 2, 2024, at
11:30 AM CDT
CatalYm today announced that positive new follow-up results from
its ongoing “GDFATHER” Phase 1/2a trial (GDF-15
Antibody-mediaTed Human Effector Cell
Relocation Phase 1/2a) will be featured in an oral
presentation at the American Society of Clinical Oncology (ASCO)
Annual Meeting 2024 in Chicago.
The trial is evaluating CatalYm’s lead GDF-15 neutralizing
antibody, visugromab, in combination with immune checkpoint
inhibitor nivolumab in late- to last-line, anti-PD-1/PD-L1
relapsed/refractory patients. Visugromab is designed to neutralize
the tumor-produced Growth Differentiation Factor-15 (GDF-15), a
central mediator of immune resistance to cancer therapies. Early
interim data of the study, which were previously presented at the
ESMO Immuno-Oncology Congress 2023, demonstrated signs for potent
and durable anti-tumor efficacy as well as an excellent
tolerability and safety profile for visugromab in combination with
nivolumab in advanced-stage/last-line non-small cell lung cancer
(NSCLC) and urothelial cancer patients (UC). Now matured data for
NSCLC, UC and novel data for hepatocellular cancer (HCC) will be
presented.
The ASCO Annual Meeting will be held in Chicago, Illinois, from
May 31 to June 4, 2024.
Oral Presentation Details:
Presentation Title: Effects of neutralization of
tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in
anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial,
and hepatocellular cancer Presenter: Dr. Ignacio Melero
Bermejo, MD | Clinica Universidad de Navarra Session:
Developmental Therapeutics-Immunotherapy Session Date and
Time: Sunday, June 2, 2024, from 11:30 AM – 1:00 PM CDT
Location: S406 | On Demand | McCormick Place Abstract
Number: 2513
The full abstract details can be accessed via
https://meetings.asco.org/abstracts-presentations/234019. The
company will provide further information and a summary of the data
following the oral presentation at ASCO.
About the GDFATHER-2 Trials
The GDFATHER-2 trial (GDF-15 Antibody-mediaTed
Human Effector cell Relocation Phase 2)
(NCT04725474) is the Phase 2a part of the ongoing Phase 1/2a trial
with several cohorts investigating the effect of visugromab
(CTL-002) in combination with a PD-1 checkpoint inhibitor in
patients in various advanced-stage/last-line and by strict criteria
anti-PD1/PD-L1 relapsed/refractory solid tumor types. The study can
enroll up to 200 patients and has extensive biomarker-evaluations
integrated to assess for potential responder patient population
identification or similar.
About Visugromab (CTL-002)
Visugromab is a monoclonal antibody that neutralizes the
tumor-derived Growth Differentiation Factor-15 (GDF-15), a locally
acting immunosuppressant fostering immunotherapy resistance.
Neutralizing GDF-15 with visugromab reverses key cancer resistance
mechanisms to reinstate an efficient anti-tumor response by
reenabling immune cell activation and tumor infiltration.
Visugromab has demonstrated already in Phase 1 a good safety
profile and potent and durable anti-tumor efficacy in combination
with anti-PD-1 treatment in advanced cancer patients The antibody
is currently being investigated in ongoing Phase 2 studies in
multiple solid tumor indications.
About CatalYm
CatalYm has identified GDF-15 as a key cancer therapy resistance
mechanism and is developing it as safe and efficacious immune
therapy for solid tumors. GDF-15, an immunosuppressant important
for feto-maternal tolerance, is hijacked by cancer cells to evade
immune system attack. Visugromab, CatalYm’s lead antibody, has
demonstrated durable anti-tumor efficacy with long-lasting
objective responses in relapsed and refractory metastatic solid
tumor patients in combination with anti-PD-1 treatment. CatalYm is
now advancing to Phase 2b studies to confirm visugromab as a new
class of cancer immunotherapy in a broad range of anti-cancer
regimens.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523161993/en/
CatalYm GmbH Dr. Phil L’Huilier, CEO info@catalym.com
Media Inquiries Trophic Communications Dr. Stephanie May
or Dr. Alison Opalko Phone: +49 171 185 56 82 or +49 151 54041130
catalym@trophic.eu